Incorporating Economic Evaluations Into Decision-Making
The Ontario Experience
Bibliographic Data
| ID | 9098766 |
|---|---|
| Authors | Andreas Laupacis (0000-0003-1380-3032, Sunnybrook Health Science Centre, corresponding author) |
| Year | 2005 |
| Volume | 43 |
| Issue | 7 |
| Pages | II-15 |
| Publication date | 2005-07-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/01.mlr.0000170002.90751.1a |
| PMID | 16056004 |
| OpenAlex | W2057822986 |
| Language | EN |
| Citations received | 4 |
| References cited | 4 |
The Drug Quality and Therapeutics Committee (DQTC) and the Canadian Expert Drug Assessment Committee (CEDAC) make reimbursement recommendations to publicly funded outpatient drug plans in Ontario and Canada respectively. In this article, the organization and decision-making processes of these committees are described. Issues associated with these committees such as potential biases associated with pharmaceutical company submissions, transparency, restricted access programs, conditional listing, and price negotiation are discussed
Actuarial science · Business · Drug pricing · Health care · Listing (finance) · Negotiation · Political science · Quality (philosophy) · Reimbursement · Transparency (behavior) · Finance · Health Systems, Economic Evaluations, Quality of Life · Law · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare
| Citations per year | 0.19 |
|---|---|
| Citation span | 2005 - 2007 (3) |
| Highly cited | No |